Copy the page URI to the clipboard
Wang, Yuzhuo; Scurll, Joshua; Rascón, Itzel Astiazarán; Cui, Cassandra; Ni, Yuchao; Shi, Ace Mingchen; Gangadharannambiar, Priyadarsini; Wang, Yu; Akamatsu, Shusuke; Beltran, Himisha; Cox, Michael; Crea, Francesco; Daugaard, Mads; Dong, Xuesen; Haffner, Michael; He, Hansen; Jachetti, Elena; Kyprianou, Natasha; Li, Benyi; Ong, Christopher E; Rickman, David S; Sen, Triparna; Zhu, Helen He; Zoubeidi, Amina and Gleave, Martin E
(2024).
DOI: https://doi.org/10.1080/17501911.2024.2391729
Abstract
Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer (PCa), emerging from advanced treatments and characterized by loss of androgen receptor (AR) signaling and neuroendocrine features, leading to rapid progression and treatment resistance. The third symposium on treatment-induced NEPC, held from 21 to 23 June 2024, at Harrison Hot Springs Resort, BC, Canada, united leading global researchers and clinicians. Sponsored by the Vancouver Prostate Centre (VPC), Canadian Institute of Health Research, Prostate Cancer Foundation Canada and Pharma Planter Inc, the event focused on the latest NEPC research and innovative treatment strategies. Co-chaired by Drs. Yuzhuo Wang and Martin Gleave, the symposium featured sessions on NEPC’s historical context, molecular pathways, epigenetic regulation and the role of the tumor microenvironment and metabolism in its progression. Keynotes from experts like Dr. Himisha Beltran and Dr. Martin Gleave highlighted the complexity of NEPC. The Emerging Talent session showcased new research, pointing to the future of NEPC treatment. The symposium concluded with a consensus on the need for early detection, targeted therapies and personalized medicine to effectively combat NEPC, emphasizing the importance of global collaboration in advancing NEPC understanding and treatment.